Strategic Collaboration Kling Biotherapeutics has established a high-potential collaboration with Sanofi for discovery of antibodies and epitopes using Kling-Select, presenting a ready-made entry point for co-development, licensing, or funded research opportunities with a major pharma partner.

Platform Versatility With Kling-Select and Kling-Evolve, the company offers a dual capability: target discovery from patient-derived B cells and rapid affinity/maturation of antibodies. This creates cross-sell opportunities across infectious disease programs, oncology assets, and emerging viral variant responses.

Clinical-Stage Feed KBA1412 is in Phase I and multiple preclinical programs are in the pipeline, indicating a portfolio with near-term development timelines and potential for out-licensing or milestone-driven deals to fund expansion.

Global Expansion Headquartered in Amsterdam with a privately held structure and a growing IP portfolio, Kling Biotherapeutics is positioned to pursue international collaborations and licensing deals, particularly in Europe and with global pharma partners seeking novel antibody platforms.

Public Wins Recent leadership appointment of a CSO and notable press about Sanofi collaboration signal market validation and credibility, improving the likelihood of attracting new investors, co-development partners, and grant or milestone funding.